Gilgamesh Pharmaceuticals
Gilgamesh Pharmaceuticals is a clinical-stage neuroscience biotech focused on developing innovative new chemical entities (NCEs) that transform psychiatric disease treatment from symptom management to rapid-acting, durable therapies. Their AI-powered discovery and translational platform accelerates novel precision psychiatric therapies development, including NMDAR antagonists, 5-HT2AR agonists, neuroplastogens, and safer ibogaine analogs targeting depression, anxiety, opioid use disorder, PTSD, and TBI. The company has demonstrated clinical progress with positive Phase 2a results and collaborations with pharma partners, positioning it as a leader in next-generation mental health therapeutics.
Gilgamesh Pharmaceuticals
Gilgamesh Pharmaceuticals is a clinical-stage neuroscience biotech focused on developing innovative new chemical entities (NCEs) that transform psychiatric disease treatment from symptom management to rapid-acting, durable therapies. Their AI-powered discovery and translational platform accelerates novel precision psychiatric therapies development, including NMDAR antagonists, 5-HT2AR agonists, neuroplastogens, and safer ibogaine analogs targeting depression, anxiety, opioid use disorder, PTSD, and TBI. The company has demonstrated clinical progress with positive Phase 2a results and collaborations with pharma partners, positioning it as a leader in next-generation mental health therapeutics.